GSKGSK Plc

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

Emma N. Walmsley

Location

N/A, N/A

Exchange

NYSE

Website

https://gsk.com

Summary

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products.

Company Info

CEO

Emma N. Walmsley

Location

N/A, N/A

Exchange

NYSE

Website

https://gsk.com

Summary

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products.

AI Insights for GSK
5 min read

Quick Summary

GSK Plc is a global biopharmaceutical company focused on discovering, developing, manufacturing, and marketing prescription medicines, vaccines, and health-related products. The company operates across Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare-related legacy activities, with its post-Haleon strategy centered more heavily on higher-growth medicines and vaccines. Its therapeutic focus includes HIV, respiratory disease, immunology, oncology, antivirals, central nervous system disorders, cardiovascular conditions, and urogenital products. GSK sells primarily to healthcare systems, governments, hospitals, clinics, pharmacies, physicians, and patients through prescription and vaccination channels. The company is listed on the NYSE as GSK and is structured as a depositary receipt, with headquarters associated with Brentford. Its latest provided fundamentals show annual revenue of about $43.93 billion, net income of about $8.46 billion, and a market capitalization of about $92.70 billion.

Strengths

•

GSK’s primary strength is its large, diversified portfolio of prescription medicines and vaccines in markets with substantial medical need.

•

The company has strong positions in HIV, respiratory, immunology, oncology, and vaccines, giving it multiple growth avenues rather than dependence on a single product.

•

Its Specialty Medicines unit is an important growth engine and supports the company’s post-Haleon focus on higher-value pharmaceuticals and vaccines.

•

GSK also benefits from global scale, established regulatory expertise, deep relationships with healthcare systems, and significant operating profitability.

•

The stock’s relatively modest valuation and dividend yield can make it attractive to investors seeking defensive healthcare exposure with income potential.

Key Risks

•

GSK faces material risks from competition, regulation, clinical trial uncertainty, and product lifecycle pressure.

•

Pfizer, Moderna, AstraZeneca, Bristol Myers Squibb, Johnson & Johnson, and other large drugmakers can challenge GSK in vaccines, oncology, HIV, respiratory, and immunology markets.

•

U.S. drug pricing reform, including IRA-related impacts, could pressure revenue and margins for selected products.

•

Regulatory setbacks, safety signals, label restrictions, or failed clinical trials could reduce expected pipeline value quickly.

What to Watch

The most recent data set is labeled 2026 Q4, but the revenue, operating income, and net income figures provided appear to be annual or full-period fundamentals rather than standalone quarterly results.
On that basis, the clearest recent financial snapshot is full-period revenue of about $43.93 billion, operating income of about $10.67 billion, and net income of about $8.46 billion, while the next scheduled earnings date is listed as November 4, 2026.
During the latest dated dividend cycle in the data, GSK declared a $0.45152 per ADS dividend on July 28, 2026, with an ex-dividend and record date of August 14, 2026, and payment scheduled for October 8, 2026.
A further $0.45152 dividend is listed with payment expected on January 7, 2027, but declaration, ex-dividend, and record dates are not provided.
Key investor focus for the quarter was likely on whether Specialty Medicines and vaccines could sustain earnings momentum, as well as on upcoming earnings commentary, pipeline updates, and guidance around vaccine demand and patent exposure.

Price Drivers

•

GSK’s stock price is being driven by a combination of earnings growth, Specialty Medicines momentum, vaccine performance, pipeline expectations, and valuation.

•

The provided fundamentals show a price-to-earnings ratio of about 13.44, an earnings yield of about 7.44%, and a dividend yield of about 3.75%, which may appeal to value and income investors.

•

Strong sales growth, higher guidance, and rising contributions from HIV, oncology, respiratory, and immunology medicines would be positive catalysts.

•

At the same time, weaker vaccine demand, Shingrix moderation, HIV patent expirations, drug-pricing pressure, and legal or regulatory concerns can weigh on sentiment.

•

The low beta of 0.28 suggests the shares may move less than the broader market, but company-specific clinical, regulatory, and competitive developments remain important drivers.

Recent News

•

Recent company-related focus has centered on GSK’s Specialty Medicines growth, vaccine performance, pipeline execution, and shareholder returns.

•

The provided data shows CEO Emma N.

•

Walmsley as chief executive and lists the next earnings date as November 4, 2026.

•

The dividend record shows continued quarterly distributions, including a $0.45152 dividend declared on July 28, 2026 and paid on October 8, 2026, plus another $0.45152 payment scheduled for January 7, 2027.

•

Investors are also monitoring potential pressure from vaccine competition, HIV patent exposure, drug-pricing reform, and oncology label dynamics.

•

With a market capitalization of about $92.70 billion and a dividend yield near 3.75%, GSK remains closely followed as a large-cap defensive pharmaceutical stock.

Market Trends

•

The pharmaceutical market is being shaped by demand for specialty medicines, biologics, oncology therapies, long-acting treatments, and adult vaccines.

•

Investors increasingly reward companies that can show durable growth beyond patent cliffs and demonstrate that pipelines can replace older products.

•

Vaccine markets remain attractive but more competitive, especially in RSV, shingles, influenza, and respiratory disease prevention.

•

Drug pricing scrutiny, reimbursement pressure, and government negotiation policies are important headwinds for large pharmaceutical companies, particularly in the United States.

•

At the same time, aging populations, chronic disease prevalence, and scientific advances in immunology, oncology, and infectious disease continue to support long-term demand for companies like GSK.

AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.

Community Research

Research from investors like you

Be the first to share your analysis on GSK

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

avatar
@democratiCrayn 8 months ago

Antibiotics market projected to reach $70.6B by 2031 with 4% annual growth

Antibiotics market projected to reach $70.6B by 2031 with 4% annual growth

post thumbnail
avatar
@starcahier 10 months ago

Markets tanked today on Greenland tariff fears

Markets tanked today on Greenland tariff fears

post thumbnail
avatar
@MasonCarter10 10 months ago

U.S. Vaccine Makers Face Demand Chill as Policy Shifts Shake Confidence

U.S. Vaccine Makers Face Demand Chill as Policy Shifts Shake Confidence

Vaccine makers in the U.S. are feeling a real chill in demand and investor confidence as sweeping policy changes under Health Secretary Robert F. Kennedy Jr. shift longstanding vaccination recommendations and dilute broad vaccine guidance. Long-standing inoculation schedules (like flu and hepatitis shots for kids) have been cut back, expert advisory panels replaced, and COVID vaccine recommendations for pregnant women and children dropped, moves that are now translating into lower usage and weaker sales forecasts. Investors say this uncertainty has dented the growth case for some biotech names and could weigh on revenues for years. Big pharma names like , , , and smaller players like , , are now having to wrestle with a more unpredictable U.S. vaccine market while broader public health experts warn of rising preventable disease risk. This isn’t just political noise anymore, policy shifts are hitting the core of vaccine demand, making it harder for some companies to forecast growth and justify investment. How much do you think U.S. policy shifts will dent long-term vaccine demand and biotech investor confidence?

avatar
@ShallowLoving 10 months ago

Respiratory vaccine market projected to reach $98B by 2035

Respiratory vaccine market projected to reach $98B by 2035

post thumbnail
avatar
@ShallowLoving 11 months ago

Trump admin signs pricing and tariff deals with 9 major pharma companies

Trump admin signs pricing and tariff deals with 9 major pharma companies

post thumbnail
avatar
@BrianHoward 12 months ago

The Oncology specialist vs up and coming

The Oncology specialist vs up and coming

that is already a major player in immuno-oncology with Opidivo, Yervoy vs   that is still growing Oncology division with drugs like Zejula and Jemperli. While BMY is strictly a bio-pharmaceutical company while GSK is slightly more diversified with the tag of being world's biggest vaccine manufacturer. Which of these two is more lucrative  to you, given that both have approximately the same market cap of about $94B and also about same figure for the revenue too?

No more topics to show